327 related articles for article (PubMed ID: 25519701)
1. Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.
Adelaiye R; Ciamporcero E; Miles KM; Sotomayor P; Bard J; Tsompana M; Conroy D; Shen L; Ramakrishnan S; Ku SY; Orillion A; Prey J; Fetterly G; Buck M; Chintala S; Bjarnason GA; Pili R
Mol Cancer Ther; 2015 Feb; 14(2):513-22. PubMed ID: 25519701
[TBL] [Abstract][Full Text] [Related]
2. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.
Hammers HJ; Verheul HM; Salumbides B; Sharma R; Rudek M; Jaspers J; Shah P; Ellis L; Shen L; Paesante S; Dykema K; Furge K; Teh BT; Netto G; Pili R
Mol Cancer Ther; 2010 Jun; 9(6):1525-35. PubMed ID: 20501804
[TBL] [Abstract][Full Text] [Related]
3. EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.
Adelaiye-Ogala R; Budka J; Damayanti NP; Arrington J; Ferris M; Hsu CC; Chintala S; Orillion A; Miles KM; Shen L; Elbanna M; Ciamporcero E; Arisa S; Pettazzoni P; Draetta GF; Seshadri M; Hancock B; Radovich M; Kota J; Buck M; Keilhack H; McCarthy BP; Persohn SA; Territo PR; Zang Y; Irudayaraj J; Tao WA; Hollenhorst P; Pili R
Cancer Res; 2017 Dec; 77(23):6651-6666. PubMed ID: 28978636
[TBL] [Abstract][Full Text] [Related]
4. MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model.
Diaz-Montero CM; Mao FJ; Barnard J; Parker Y; Zamanian-Daryoush M; Pink JJ; Finke JH; Rini BI; Lindner DJ
Br J Cancer; 2016 Oct; 115(8):920-928. PubMed ID: 27560553
[TBL] [Abstract][Full Text] [Related]
5. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
Shibasaki N; Yamasaki T; Kanno T; Arakaki R; Sakamoto H; Utsunomiya N; Inoue T; Tsuruyama T; Nakamura E; Ogawa O; Kamba T
PLoS One; 2015; 10(6):e0130980. PubMed ID: 26114873
[TBL] [Abstract][Full Text] [Related]
6. Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.
Su SC; Hu X; Kenney PA; Merrill MM; Babaian KN; Zhang XY; Maity T; Yang SF; Lin X; Wood CG
Clin Cancer Res; 2013 Dec; 19(23):6461-72. PubMed ID: 24122794
[TBL] [Abstract][Full Text] [Related]
7. Targeting renal cell carcinoma with a HIF-2 antagonist.
Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
[TBL] [Abstract][Full Text] [Related]
9. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
[TBL] [Abstract][Full Text] [Related]
10. Monitoring the Vascular Response and Resistance to Sunitinib in Renal Cell Carcinoma
Robinson SP; Boult JKR; Vasudev NS; Reynolds AR
Cancer Res; 2017 Aug; 77(15):4127-4134. PubMed ID: 28566330
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma.
Huang D; Ding Y; Zhou M; Rini BI; Petillo D; Qian CN; Kahnoski R; Futreal PA; Furge KA; Teh BT
Cancer Res; 2010 Feb; 70(3):1063-71. PubMed ID: 20103651
[TBL] [Abstract][Full Text] [Related]
12. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma.
Prior C; Perez-Gracia JL; Garcia-Donas J; Rodriguez-Antona C; Guruceaga E; Esteban E; Suarez C; Castellano D; del Alba AG; Lozano MD; Carles J; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Gurpide A; Lopez-Picazo JM; Hernandez AG; Mellado B; Martínez E; Moreno F; Font A; Calvo A
PLoS One; 2014; 9(1):e86263. PubMed ID: 24475095
[TBL] [Abstract][Full Text] [Related]
13. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.
Garcia-Donas J; Esteban E; Leandro-García LJ; Castellano DE; González del Alba A; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Mellado B; Martínez E; Moreno F; Font A; Robledo M; Rodríguez-Antona C
Lancet Oncol; 2011 Nov; 12(12):1143-50. PubMed ID: 22015057
[TBL] [Abstract][Full Text] [Related]
14. Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.
Garcia-Donas J; Leandro-García LJ; González Del Alba A; Morente M; Alemany I; Esteban E; Arranz JA; Climent MA; Gallardo E; Castellano DE; Bellmunt J; Mellado B; Puente J; Moreno F; Font A; Hernando S; Robledo M; Rodríguez-Antona C
Ann Oncol; 2013 Sep; 24(9):2409-14. PubMed ID: 23788753
[TBL] [Abstract][Full Text] [Related]
15. PRKX, TTBK2 and RSK4 expression causes Sunitinib resistance in kidney carcinoma- and melanoma-cell lines.
Bender C; Ullrich A
Int J Cancer; 2012 Jul; 131(2):E45-55. PubMed ID: 22020623
[TBL] [Abstract][Full Text] [Related]
16. Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway.
Gao Y; Li J; Qiao N; Meng Q; Zhang M; Wang X; Jia J; Yang S; Qu C; Li W; Wang D
Oncotarget; 2016 Sep; 7(39):63374-63387. PubMed ID: 27556517
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.
Miyazaki A; Miyake H; Fujisawa M
Clin Transl Oncol; 2016 Sep; 18(9):893-900. PubMed ID: 26597115
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
19. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models.
Ciamporcero E; Miles KM; Adelaiye R; Ramakrishnan S; Shen L; Ku S; Pizzimenti S; Sennino B; Barrera G; Pili R
Mol Cancer Ther; 2015 Jan; 14(1):101-10. PubMed ID: 25381264
[TBL] [Abstract][Full Text] [Related]
20. Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.
Serova M; Tijeras-Raballand A; Dos Santos C; Martinet M; Neuzillet C; Lopez A; Mitchell DC; Bryan BA; Gapihan G; Janin A; Bousquet G; Riveiro ME; Bieche I; Faivre S; Raymond E; de Gramont A
Oncotarget; 2016 Jun; 7(25):38467-86. PubMed ID: 27509260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
